Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
Ensem Therapeutics
Varian, a Siemens Healthineers Company
PMV Pharmaceuticals, Inc
Kivu Bioscience Inc.
FindCure Biosciences (ZhongShan) Co., Ltd.
Hoffmann-La Roche
UMC Utrecht
AstraZeneca
University of Chicago
University of California, Irvine
Eastern Cooperative Oncology Group
Eli Lilly and Company
ViroMissile, Inc.
Terremoto Biosciences Inc.
Hospices Civils de Lyon
University Health Network, Toronto
Jazz Pharmaceuticals
Kaiser Permanente
Duke University
Washington University School of Medicine
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Poseida Therapeutics, Inc.
IDEAYA Biosciences
Baylor College of Medicine
University of Colorado, Denver
MacroGenics
Avacta Life Sciences Ltd
Alliance for Clinical Trials in Oncology
SystImmune Inc.
Daiichi Sankyo
SN BioScience
Memorial Sloan Kettering Cancer Center
University of Nebraska
Takeda
Oscotec Inc.
Kidney Cancer Research Bureau
Adela, Inc
Second Life Therapeutics
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fusion Pharmaceuticals Inc.
Eli Lilly and Company
Varian, a Siemens Healthineers Company
Sichuan Baili Pharmaceutical Co., Ltd.
Brigham and Women's Hospital
The Netherlands Cancer Institute
Jacobio Pharmaceuticals Co., Ltd.
Var2 Pharmaceuticals